The benefit of a trial on ACE2, COVID-19 and RAAS pharmacotherapies pharmacogenetics is that these medications are already FDA approved and most are in generic form which should shorten the time for these clinical trials while even more promising new therapies (including those that specifically target coronaviruses with a focus on membrane-bound versus circulating ACE2) are moving through phased clinical trials. Here, ACE2 is linked to COVID-19.